{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-354780","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2026-08-18T12:39:19+00:00","discovered_at":"2026-08-18T12:40:04.963498+00:00","generated_at":"2026-08-18T12:40:12.620949+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioMarin to acquire Alesta Therapeutics for $275M upfront plus $215M milestones","bullets":["Upfront $275M cash plus up to $215M in development/regulatory milestone payments.","Gains ALE1, potential first oral therapy for hypophosphatasia (HPP), in Phase 1/2a.","Alesta spins out non-ALE1 assets and employees transfer to spinout before close.","Expected to close Q3 2026; funded with cash on hand; modestly dilutive to 2026 results.","BioMarin CEO cites strategic fit and larger rare disease market opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-354780","json":"https://secwatch.observer/filing/0001193125-26-354780.json","markdown":"https://secwatch.observer/filing/0001193125-26-354780.md","text":"https://secwatch.observer/filing/0001193125-26-354780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526354780/0001193125-26-354780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312526354780/d172628d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-18T12:40:12.620949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}